



Cervical Cancer

Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570 000 women were diagnosed with cervical cancer worldwide and about 311 000 women died. Almost all cervical cancer cases (99%) are linked to infection with high-risk human papillomaviruses (HPV), an extremely common virus transmitted through sexual contact. Effective primary (HPV vaccination) and secondary prevention approaches (screening for, and treating precancerous lesions) will prevent most cervical cancer cases.

Rapid and easy tests are needed to screen quickly cancer and improve treatment.

Our PapilloDia rapid test detects specific HPV 16/18 E6 & E7 oncoproteins in cervical swab samples to help healthcare professional to diagnose and screen quickly cervical cancer.

Test Procedure



Diagnostic Performance

		Immunohistochemistry (IHC)		
		+	-	Total
PapilloDia Rapid test	+	58	21	79
	-	13	169	182
	Total	71	190	261
Sensitivity	81.7%	(CI95%: 70.4-89.5%)		
Specificity	88.9%	(CI95%: 83.4-92.9%)		
PPV	73.4%	(CI95%: 62.1-82.4%)		
NPV	92.9%	(CI95%: 87.8-96.0%)		

PapilloDia - Rapid diagnostic test Kit

Catalog Number: CER-020 -- 20 tests per kit

Content: 20 tests in pouch, 1 extraction Buffer A, 1 extraction Buffer B, 20 extraction tubes, 1 workstation, 1 Instruction for Use, 1 Quick guide

CONTACT: info@gadia.net

Product not available in all countries. Not available for sales in United States

www.gadia.net

GaDia SA is ISO13485:2016 certified

GaDia SA
Route de l'île aux bois 1A
1870 Monthey (Switzerland)